RIVERMARK MEDICAL ANNOUNCES FIRST PATIENT ENROLLED IN RAPID III CLINICAL STUDY EVALUATING THE FLOSTENT™ SYSTEM

Study to assess safety and effectiveness of a minimally invasive, zero-capital, outpatient device therapy for BPH MILWAUKEE, April 23, 2025 /PRNewswire/ -- Rivermark Medical, a urology-focused medical device company committed to redefining benign prostatic hyperplasia (BPH) treatment...